MX2015017654A - Formulacion intravenosa estable. - Google Patents

Formulacion intravenosa estable.

Info

Publication number
MX2015017654A
MX2015017654A MX2015017654A MX2015017654A MX2015017654A MX 2015017654 A MX2015017654 A MX 2015017654A MX 2015017654 A MX2015017654 A MX 2015017654A MX 2015017654 A MX2015017654 A MX 2015017654A MX 2015017654 A MX2015017654 A MX 2015017654A
Authority
MX
Mexico
Prior art keywords
intravenous formulation
fluoro
chloro
methoxy
phenyl
Prior art date
Application number
MX2015017654A
Other languages
English (en)
Inventor
Anthony N Galasso
Petra Inbar
Farooq Qureshi
Harendra R Sampat
Shangdong Zhan
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2015017654A publication Critical patent/MX2015017654A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporciona una formulación liofilizada estable para la administración intravenosa del compuesto 4-{[(2R, 3S, 5S)-4-(4-cloro-2-fluor-fenil)-3-(3-cloro-2-fluor-fenil)-4-ciano-5 -(2,2-dimetil-propil)-pirrolidina-2-carbonil)-amino}-3- metoxi-benzoato de 1-[2-(2-metoxi-etoxi)-etoxicarboniloxi]- etilo.
MX2015017654A 2013-06-24 2014-06-20 Formulacion intravenosa estable. MX2015017654A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361838642P 2013-06-24 2013-06-24
US201361840930P 2013-06-28 2013-06-28
PCT/EP2014/062982 WO2014206866A1 (en) 2013-06-24 2014-06-20 Stable intravenous formulation

Publications (1)

Publication Number Publication Date
MX2015017654A true MX2015017654A (es) 2016-04-15

Family

ID=51014281

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015017654A MX2015017654A (es) 2013-06-24 2014-06-20 Formulacion intravenosa estable.

Country Status (15)

Country Link
US (2) US20160136280A1 (es)
EP (1) EP3013316B1 (es)
JP (1) JP6346945B2 (es)
KR (1) KR20160011668A (es)
CN (1) CN105338959A (es)
AR (1) AR096710A1 (es)
AU (1) AU2014301324A1 (es)
BR (1) BR112015029976A2 (es)
CA (1) CA2913174A1 (es)
HK (1) HK1214531A1 (es)
MX (1) MX2015017654A (es)
RU (1) RU2015154097A (es)
SG (1) SG11201510654WA (es)
WO (1) WO2014206866A1 (es)
ZA (1) ZA201508641B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3498712B1 (en) * 2016-08-08 2024-01-03 Jiangsu Yayo Biotechnology Co. Ltd Spirocyclic indolone polyethylene glycol carbonate compound, composition, preparation method and use thereof
GB201919219D0 (en) 2019-12-23 2020-02-05 Otsuka Pharma Co Ltd Cancer biomarkers
US20230313313A1 (en) 2020-08-27 2023-10-05 Otsuka Pharmaceutical Co., Ltd. Biomarkers for cancer therapy using mdm2 antagonists
GB202103080D0 (en) 2021-03-04 2021-04-21 Otsuka Pharma Co Ltd Cancer biomarkers

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08157491A (ja) * 1994-11-30 1996-06-18 Hayashibara Biochem Lab Inc トレハロース誘導体の製造方法
US5747058A (en) * 1995-06-07 1998-05-05 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
US20040033228A1 (en) * 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
JP4917263B2 (ja) * 2002-12-23 2012-04-18 バイカル インコーポレイテッド 核酸／ブロックコポリマー／陽イオン性界面活性剤複合体を凍結乾燥する方法
US9308257B2 (en) * 2007-11-28 2016-04-12 Medimmune, Llc Protein formulation
US8354444B2 (en) * 2008-09-18 2013-01-15 Hoffmann-La Roche Inc. Substituted pyrrolidine-2-carboxamides
CN103857440B (zh) * 2011-06-22 2018-09-25 维奥姆生物科学有限公司 基于缀合物的抗真菌和抗细菌前药
JP2013018737A (ja) * 2011-07-11 2013-01-31 Fujifilm Corp 凍結乾燥製剤及びその製造方法
US8993614B2 (en) * 2012-03-15 2015-03-31 F. Hoffmann-La Roche Ag Substituted pyrrolidine-2-carboxamides

Also Published As

Publication number Publication date
CN105338959A (zh) 2016-02-17
KR20160011668A (ko) 2016-02-01
EP3013316A1 (en) 2016-05-04
ZA201508641B (en) 2017-09-27
US20160136280A1 (en) 2016-05-19
WO2014206866A1 (en) 2014-12-31
RU2015154097A (ru) 2017-07-26
AU2014301324A1 (en) 2015-12-10
US20180071393A1 (en) 2018-03-15
JP2016522239A (ja) 2016-07-28
SG11201510654WA (en) 2016-01-28
EP3013316B1 (en) 2018-05-30
HK1214531A1 (zh) 2016-07-29
CA2913174A1 (en) 2014-12-31
AR096710A1 (es) 2016-01-27
BR112015029976A2 (pt) 2017-07-25
JP6346945B2 (ja) 2018-06-20

Similar Documents

Publication Publication Date Title
PH12016500467A1 (en) Aminoheteroarlyl benzamides as kinase inhibitors
NZ626505A (en) Substituted pyrrolidine-2-carboxamides
IN2014CN03803A (es)
PE20151335A1 (es) Composicion farmaceutica con biodisponibilidad mejorada
PH12015502031A1 (en) Tetrahydropyrrolothiazine compounds
AU2012259422A8 (en) Solid forms of a pharmaceutically active substance
MX2015011913A (es) Moduladores de acido oxabiciclo[2.2.2] gpr120.
MX2015015562A (es) Dihidropiridinona como inhibidores de monoacilglicerol aciltransferasa 2.
MX2015017654A (es) Formulacion intravenosa estable.
MX2015011932A (es) Moduladores de gpr120 de acido biciclo[2.2.2].
WO2016068580A3 (en) Novel pyridopyrimidinone compounds for modulating the catalytic activity of histone lysine demethylases (kdms)
CO7081156A2 (es) Sales de 5-[(1r)-2-({2-[4-(2,2-difluoro-2-feniletoxi)fenil] etil}amino)-1-hidroxietil]-8-hidroxiquinolin-2(1h)-ona
NZ602710A (en) Use of novel pan-cdk inhibitors for treating tumors
EA201591795A1 (ru) Бицикло[2.2.1]-кислоты в качестве модуляторов рецептора gpr120
MX2015016332A (es) Inhibidores de alk biciclicos fusionados.
PH12016500577B1 (en) Piperazine derivatives and the use thereof as medicament
AU2014220865A8 (en) Asymmetric synthesis of a substituted pyrrolidine-2-carboxamide
EP4282973A3 (en) Processes for the preparation of pyrimidinylcyclopentane compounds
RS54689B1 (en) CONNECTED BICYCLIC 2,4- DIAMINOPYRIMIDINE DERIVATIVE AS DUAL ALK AND FAK INHIBITOR
EA201400473A1 (ru) Способ синтеза 3,4-диметоксибицикло[4.2.0]окта-1,3,5-триен-7-карбонитрила и применение для синтеза ивабрадина и его солей присоединения с фармацевтически приемлемой кислотой
EA201301136A3 (ru) Новый способ синтеза (2e)-3-(3,4-диметоксифенил)проп-2-еннитрила, применение в синтезе ивабрадина и его фармацевтически приемлемых кислотно-аддитивных солей
MX2013002656A (es) Nuevo proceso.
SA114350383B1 (ar) عملية لتخليق مركبات 7، 8 - داي ميثوكسي - 1 ،3- داي هيدرو -h2 -3- بنزازيبين -2- أون، وتطبيقها في تخليق إيفابرادين
RU2010138237A (ru) N-(2-бензотиазолил)амид 3-бром-2,4-диоксо-4-(4-метоксифенил)бутановой кислоты, обладающий гипогликемической активностью